MedTrace Logo

A Study to Evaluate the PK, Safety and Tolerability of HCP1803.

NCT05723549 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2023-09-22

No results posted yet for this study

Summary

A randomized, open-label, single-dose parallel study to evaluate the pharmacokinetics, safety and tolerability of HCP1803 in healthy male volunteers.

Conditions

  • Healthy

Interventions

DRUG

HCP1803-3

Take it once per period

DRUG

RLD2002

Take it once per period

DRUG

HCP1904-1

Take it once per period

Sponsors & Collaborators

  • Hanmi Pharmaceutical Company Limited

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-02-02
Primary Completion
2023-03-20
Completion
2023-03-20

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05723549 on ClinicalTrials.gov